Replies to post #122424 on Avid Bioservices Inc (CDMO)

[entdoc]

ftm, agreed, but from a clinician's POV, all 3 of these reports are attention-getters. It is getting easier and easier for almost anyone to connect the dots. Breast cancer results are dynamite imo. Lung cancer is impressive. Soon we will be able to assess effects of Bavi in earlier disease after determining that side-effects with Bavi are no greater than those of control group. Not a home run, but methinks there we have a runner in scoring position.

[cjgaddy]

I would think they would press release ASCO’13 update(s) on Monday, after the poster presentations this weekend (Sat & Sun)…

ABSTRACT: 8095
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Presenter: Mikhail Shtivelband, MD
Track(s): Lung Cancer
Session Type: General Poster Session
Time & Location: Sat, June 1, 8:00 AM - 11:45 AM CDT, S Hall A2
Abstract Conclusions: This randomized, placebo-controlled Phase II trial demonstrated a positive trend favoring 3mg/kg dosage of bavituximab plus docetaxel in overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). 3mg/kg bavituximab in combination with docetaxel was well tolerated and is the planned dose for Phase III.

ABSTRACT: 567
Phase I clinical trial of bavituximab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).
Presenter: Pavani Chalasani, MD, MPH
Track: Breast Cancer
Session Type: General Poster Session
Time & Location: Sat, June 1, 1:15 PM - 5:00 PM CDT, S Hall A2
Abstract Conclusions: Bavituximab is well tolerated in combination with paclitaxel. Early results show promise in terms of clinical responses with 8 of 10 evaluable patients having clinical benefit. Early biomarker results suggest no effect of therapy on platelet activation but decreases in circulating microparticles is observed.

ABSTRACT: 4054
Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma.
Presenter: Shuchi S. Pandya, MD
Track: Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Time & Location: Sun, June 2, 8:00 AM - 11:45 AM CDT, S Hall A2
Abstract Conclusions: In this patient population with extensive disease burdens and limited treatment options, bavituximab plus gemcitabine was well tolerated and demonstrated moderate activity in tumor response and survival.

= = = = = = = = = = =
5-16-13: Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting
• Presentations Include Data From Two Phase II Bavituximab Trials in Second-Line NSCLC and Pancreatic Cancer and a Phase I Bavituximab Trial in HER2-Negative Breast Cancer
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=765427

May31-Jun4: ASCO Annual Mtg. 2013, Chicago (Abstracts DL=Feb5) http://chicago2013.asco.org
...Peregrine Pharm. - ASCO Exhibitor Booth #16107 ("Featured Exhibitor") http://events.jspargo.com/asco13/public/ExhibitorList.aspx?Index=P
...3 Bavi ASCO'13 posters: 2nd-Line NSCLC, Pancreatic, MBC(IST) - Abstracts (FTM): http://tinyurl.com/nvwbbkx